ArticlePsycho-oncology2025
Gender Differences in Quality of Life and Psycho-Oncological Needs During the First Year After Melanoma Diagnosis.
Article in Psycho-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cancer survivorship in malignant melanoma.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026Review
- Gender Differences in Quality of Life and Psycho-Oncological Needs During the First Year After Melanoma Diagnosis.Psycho-oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveThis study investigated the course of general well-being and health-related quality of life (HRQoL) in working-age melanoma patients during the first year following diagnosis. It also examines the use of psycho-oncological counseling and rehabilitation, and their impact on QoL.
methodsPatients aged 18-65 years with stage 0 to IIIC melanoma were eligible for this single-center, prospective cohort study. Following informed consent, clinical data and data on general well-being (WHO-5), HRQoL (FACT-M) and need for psycho-oncological care (Hornheider Screening Instrument) were collected at baseline and every three months over one year.
resultsWe included 221 melanoma patients (median age 51, range 19-65, 62% female). At baseline, 79% had melanoma stage IB or lower. After one year, 9% had progressed. 38% of patients showed a WHO-5 score below 52% following diagnosis, regardless of tumor stage. Women with stage 0 to IIA melanoma had significantly lower HRQoL in the first six months than men (p = 0.010), and a higher need for psychological support (p < 0.001). There was considerable variability in QoL trajectories both within individuals (median variation 11%) and across patients. In general, 52% needed psycho-oncological care at baseline, but neither counseling (24%) nor rehabilitation (18%) resulted in significant improvements in QoL over the year.
conclusionsMelanoma diagnosis leads to a marked QoL reduction, particularly in lower stage women, with most patients improving over time. However, substantial intra-individual variation emphasizes the need for regular QoL assessments. Further research is needed to assess the long-term effectiveness of psycho-oncological support and rehabilitation.
trial registrationGerman Clinical Trials Register No. DRKS00010005, 08. March 2016.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.